Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Medchemexpress LLC XMU-MP-3 | 2031152-08-4 | MFCD34470527; MFCD19703308 | 95.7% | 536.55 g·mol⁻¹ | C27H27F3N8O | 5 MG
SDP

Catalog No. 5000222522
Encompass_Preferred

XMU-MP-3 is a non-covalent small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with low-nanomolar biochemical potency against wild-type and C481S mutant BTK. It shows activity in BTK-dependent cellular proliferation assays and is supplied as a solid research compound with reported purity around 95.7%.

  • Potent non-covalent inhibition of BTK (WT and C481S)
  • Low-nanomolar biochemical potency suitable for in vitro studies
  • Demonstrated cellular activity in BTK-dependent proliferation assays
  • Soluble in DMSO for assay preparation
  • Available in small solid packs for preclinical research

Catalog No. 50-002-22522 Supplier Medchemexpress LLC Supplier No. HY1365315MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

XMU-MP-3 is a non-covalent small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with low-nanomolar biochemical potency against wild-type and C481S mutant BTK. It shows activity in BTK-dependent cellular proliferation assays and is supplied as a solid research compound with reported purity around 95.7%.

  • Potent non-covalent inhibition of BTK (WT and C481S)
  • Low-nanomolar biochemical potency suitable for in vitro studies
  • Demonstrated cellular activity in BTK-dependent proliferation assays
  • Soluble in DMSO for assay preparation
  • Available in small solid packs for preclinical research

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.